Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Predictive Oncology ( (POAI) ) just unveiled an update.
Predictive Oncology Inc. has announced that it has regained compliance with Nasdaq’s minimum stockholders’ equity requirement following two private investment in public equity transactions. The company received approximately $343.5 million, which included cash and in-kind contributions of crypto assets, bringing its stockholders’ equity above the required $2.5 million threshold.
The most recent analyst rating on (POAI) stock is a Sell with a $7.00 price target. To see the full list of analyst forecasts on Predictive Oncology stock, see the POAI Stock Forecast page.
Spark’s Take on POAI Stock
According to Spark, TipRanks’ AI Analyst, POAI is a Underperform.
The overall stock score is heavily impacted by significant financial challenges, including declining revenues and negative profit margins. Technical analysis indicates bearish momentum, and valuation metrics are unattractive due to ongoing losses. The absence of earnings call insights and corporate events does not alter the negative outlook.
To see Spark’s full report on POAI stock, click here.
More about Predictive Oncology
Average Trading Volume: 94,992
Technical Sentiment Signal: Sell
Current Market Cap: $21.11M
For an in-depth examination of POAI stock, go to TipRanks’ Overview page.